BioAtla Inc (NAS:BCAB)
$ 2.2 -0.15 (-6.38%) Market Cap: 106.34 Mil Enterprise Value: 46.34 Mil PE Ratio: 0 PB Ratio: 3.39 GF Score: 35/100

Q1 2023 Bioatla Inc Earnings Call Transcript

May 11, 2023 / 08:30PM GMT
Release Date Price: $3.21 (-3.02%)
Operator

Greetings, and welcome to the BioAtla, Inc. first-quarter 2023 earnings conference call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. (Operator Instructions) And as reminder, this conference is being recorded.

And it is now my pleasure to introduce to you Bruce Mackle from LifeSci Advisors. Thank you, Bruce. You may begin.

Bruce Mackle
LifeSci Advisors, LLC - IR

Thank you, operator, and good afternoon, everyone. With me today on the phone from BioAtla are Dr. Jay Short, Chairman, CEO and Co-Founder; and Richard Waldron, Chief Financial Officer. Following today's call, Richard Waldron, Chief of Clinical Development and Operations; Dr. Eric Sievers, Chief Medical Officer; and Sheri Lydick, Senior Vice President, Commercial Strategy will join Jay and Rick for a short Q&A.

Earlier this afternoon, BioAtla released financial results and a business update for the first quarter ended March 31, 2023. A copy of the press release is available on the company's

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot